/NSRX
NSRX Stock - Nasus Pharma Ltd.
Healthcare|BiotechnologyAMEX
$7.58+18.92%
+$1.21 (+18.92%) • Dec 19
79
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.56
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+190.4%upside
Target: $22.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NSRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.50 – $7.65
TARGET (TP)$22.00
STOP LOSS$6.97
RISK/REWARD1:23.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.01
52W High$9.99
52W Low$5.90
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A |
| Operating Income | $-1,078,000 | $-1,147,000 | $-2,042,000 |
| Net Income | $-1,532,000 | $-1,051,000 | $-1,711,000 |
| Net Margin | N/A | N/A | N/A |
| EPS | $-0.17 | $-0.12 | $-0.19 |
Company Overview
Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose. Their lead products include NS002, an intranasal powder epinephrine nasal spray for type 1 severe allergies and anaphylaxis, and NS001, an intranasal naloxone powder spray for opioid overdose. They use a powder-based intranasal technology that offers rapid drug absorption.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NSRXLoading earnings data...
Latest News
Citizens Initiates Coverage On Nasus Pharma with Market Outperform Rating, Announces Price Target of $19
📈 PositiveBenzinga•Dec 18, 2025, 01:13 PM
Nasus Pharma Appoints Eyal Rubin As EVP And CFO
➖ NeutralBenzinga•Nov 20, 2025, 01:16 PM
Nasus Pharma Initiates Phase 2 Clinical Study To Evaluate NS002 Investigational Intranasal Epinephrine Powder Formulation With Dosing Of First Patient To Treat Anaphylaxis
📈 PositiveBenzinga•Nov 18, 2025, 01:07 PM
Nasus Pharma Announces Health Canada Has Issued A No-Objection Letter Allowing The Company To Proceed With A Phase 2 Clinical Trial Of NS002, Its Intranasal Epinephrine Powder Being Developed For The Treatment Of Anaphylaxis
📈 PositiveBenzinga•Nov 6, 2025, 01:09 PM
Earlier Today: Nasus Pharma Executes Comprehensive Agreements With Aptar To Support Ongoing Clinical Development And Planned Commercialization Of NS002, Intranasal Powder Epinephrine Product Candidate
📈 PositiveBenzinga•Oct 8, 2025, 02:26 PM
Laidlaw & Co. Initiates Coverage On Nasus Pharma with Buy Rating, Announces Price Target of $22
📈 PositiveBenzinga•Sep 29, 2025, 12:22 PM
Frequently Asked Questions about NSRX
What is NSRX's current stock price?
Nasus Pharma Ltd. (NSRX) is currently trading at $7.58 per share. The stock has moved +18.92% today.
What is the analyst price target for NSRX?
The average analyst price target for NSRX is $22.00, based on 1 analyst.
What sector is Nasus Pharma Ltd. in?
Nasus Pharma Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the AMEX exchange.
What is NSRX's market cap?
Nasus Pharma Ltd. has a market capitalization of $0.07 billion, making it a small-cap company.
Does NSRX pay dividends?
No, Nasus Pharma Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACET
Adicet Bio, Inc.
$0.49
Mkt Cap: $0.0B
ACRV
Acrivon Therapeutics, Inc. Common Stock
$2.16
Mkt Cap: $0.1B
ADAG
Adagene Inc.
$1.82
Mkt Cap: $0.1B
CRVO
CervoMed Inc.
$7.60
Mkt Cap: $0.1B
FBIO
Fortress Biotech, Inc.
$3.54
Mkt Cap: $0.1B
GANX
Gain Therapeutics, Inc.
$2.88
Mkt Cap: $0.1B
LITS
Lite Strategy, Inc.
$1.43
Mkt Cap: $0.1B
NTRB
Nutriband Inc.
$4.49
Mkt Cap: $0.1B
TCRX
TScan Therapeutics, Inc.
$0.90
Mkt Cap: $0.1B
XBIT
XBiotech Inc.
$2.50
Mkt Cap: $0.1B
Explore stocks similar to NSRX for comparison